Borrelia miyamotoi is a relapsing fever Borrelia, transmitted by hard (Ixodes) ticks, which are also the main vector for Borrelia burgdorferi. A widely used test for serodiagnosis of Lyme borreliosis is an EIA based on the C6 peptide of the B. burgdorferi sl VlsE protein. We set out to study C6 reactivity upon infection with B. miyamotoiin a large well-characterized set of Borrelia miyamotoi disease (BMD) patient sera and in experimental murine infection.
Methods
We performed in-silico analyses, comparing the C6-peptide to immunodominant B. miyamotoi variable large proteins (Vlps). Next, we determined C6 reactivity in sera from mice infected with B. miyamotoi and in a unique longitudinal set of 191 sera from 46 BMD patients.
Results
In-silico analyses revealed similarity of the C6-peptide to domains within B. miyamotoi Vlps.Cross-reactivity against the C6-peptide was confirmed in 21/24 mice experimentally infected with B. miyamotoi.Moreover, 35/46 BMD patients had a C6 EIA Lyme-index higher than 1.1 (positive). Interestingly, 27/37 patients with a C6 EIA Lyme-index higher than 0.9 (equivocal) were negative when tested for specific B. burgdorferi sl antibodies using a commercially available immunoblot.
Conclusions
We show that infection with B. miyamotoi leads to cross-reactive antibodies to the C6-peptide. Since BMD and Lyme borreliosis are found in the same geographical locations, caution should be used when relying solely on C6-reactivity testing. We propose that a positive C6 EIA with negative immunoblot, especially in patients with fever several weeks after a tick bite, warrants further testing for B. miyamotoi.
As of 2014 Labcorp no longer allows physicians to order Western Blots for Lyme disease. The only test available is the ELISA with reflex to Western Blot if positive.
They have also taken away the C6 peptide. The results are presented as only negative if less than 0.91
Some ID doctors are inappropriately applying the HIV testing paradigm in the case of Lyme testing
The IDSA claims, without reference, there’s a lot of false positive Lyme Western Blots because of cross reactivity
The test was developed based on a meeting 20 years ago for surveillance (an epidemiology or research tool) not for diagnosis
The long arm of the IDSA has managed to promote its agenda by manipulating the CDC and now Labcorp
CDC’s Dr. Beard’s s comment to the author was an admission that politics have trumped reason, logic and science when he stated about the flawed testing, “Well, that’s the party line.”
The testing stronghold dilemma continues unabated in the topsy-turvy world of Lymeland.
Remember….
“I am Barbara Johnson. I am a biochemist by training and I am speaking today on behalf of the Centers for Disease Control and Prevention concerning serodiagnosis of Lyme disease. Specifically, my statement is in support of (the) IDSA recommendation in the guidelines to use two-tiered serology (an ELISA screening test followed by Western Blots if ELISA positive) to support the diagnosis of Lyme disease in patients who have manifestations other than acute erythema migrans.– IDSA Lyme Disease Review Panel Hearing, July 30, 2009
A new blood test to detect brain changes emblematic of early Alzheimer’s disease (AD) has moved one step closer to reality and could be a “game changer” for the field.
Researchers found that measuring the ratio of β-amyloid (Aβ) 42 and Aβ40 in blood using a high-precision assay is 94% accurate in diagnosing brain amyloidosis, using amyloid PET or CSF phosphorylated (p-tau) 181/Aβ42 as reference standards.
“Right now we screen people for clinical trials with brain scans, which is time-consuming and expensive, and enrolling participants takes years,” senior investigator Randall J. Bateman, MD, professor of neurology, Washington University School of Medicine in St. Louis, said in a statement.
“But with a blood test, we could potentially screen thousands of people a month. That means we can more efficiently enroll participants in clinical trials, which will help us find treatments faster, and could have an enormous impact on the cost of the disease as well as the human suffering that goes with it,” he added.
Using an immunoprecipitation and liquid chromatography–mass spectrometry assay, the researchers measured Aβ42/Aβ40 in plasma and CSF samples from 158 older, mostly cognitively normal individuals (94% with Clinical Dementia Rate [CDR] = 0) that were collected within 18 months of an amyloid PET scan.
Plasma Aβ42/Aβ40 correlated highly with amyloid PET status (receiver operating characteristic area under the curve [AUC], 0.88; 95% confidence interval [CI], 0.82 – 0.93) and CSF p-tau181/Aβ42 (AUC, 0.85; 95% CI, 0.79 – 0.92), the researchers report.
The combination of plasma Aβ42/Aβ40, age, and apolipoprotein (APOE) ε4 status had “very high” correlation with amyloid PET (AUC, 0.94; 95% CI, 0.90 – 0.97), “suggesting that plasma Aβ42/Aβ40 may be used as a screening tool for those at risk of AD dementia,” the researchers write.
In addition, individuals with a positive plasma Aβ42/Aβ40 but negative amyloid PET scan have a 15-fold higher risk of converting to amyloid PET-positive (P = .01).
“The sensitivity of the plasma Aβ42/Aβ40 assay to amyloid PET-negative individuals who convert to amyloid PET-positive suggests that plasma Aβ42/Aβ40 becomes positive earlier than the established amyloid PET threshold used for this study,” Bateman and colleagues note in their report.
“Therefore, a positive plasma Aβ42/Aβ40 with a negative amyloid PET scan may represent early amyloidosis rather than a false-positive result in some individuals,” they add.
As reportedby Medscape Medical News, the study builds on earlier work by the same researchers.
Reading a diagnostic company’s menu can often feel like interpreting another language. The commonly used name of an infection may not be listed, and the scientific name of the pathogen may not be familiar (e.g., Lyme disease vs. Borrelia burgdorferi).
To make things more difficult, acronyms for the testing methods can seem like randomly grouped letters for those of us who are not researchers or do not work in a clinical setting. Serology, an umbrella term for testing serum, is a common method that Galaxy Diagnostics customers frequently contact us for help deciphering.
The most basic definition of serology is “the study of blood serum”. Blood serum is created when clotted blood is collected in a serum-separator tube and then spun in a centrifuge at high speed. This forces red and white blood cells through a gel matrix at the bottom of the tube, leaving a clear to yellowish liquid called serum. The components that remain include electrolytes (sodium, potassium, etc.), hormones, and an assortment of proteins.
Immunoglobulins (Ig), or antibodies, can be found in serum and are useful for vector-borne disease testing. They are proteins created by the immune system when a foreign substance invades the bloodstream. The development of these proteins may be delayed, suppressed or altered if a person’s immune system is different for a variety of reasons, including the use of immune suppressing medications or the presence of an autoimmune condition such as lupus.
The foreign substance, called an antigen, could be a wide variety of things, such as a toxic by-product of pathogen metabolism, a protein located on the surface of the bacteria itself, or a virus. White blood cells, specifically B cells, bind antigens and create unique antibodies that help mount a strong immune response.
In humans, typical antibodies are shaped like a “Y” and have two binding sites that are specific to an antigen. As they float around the bloodstream, they can bind the antigens that they were created to match. Once an antigen is bound, it may be broken down immediately or another immune cell, such as a T-cell, may be signaled to destroy it. In a sense, antibodies act as the whistle blowers of the immune system.
There are five classes of antibodies:
IgA
IgE
IgD
IgM
IgG
Antibodies that are relevant for vector-borne serology testing are IgM and IgG. However, IgM only make up about 5-10% of the total blood serum, whereas IgG make up about 75-80%. So why test for both?
Generally, when a new antigen is encountered, B-cells produce about six times more IgM than IgG. IgM are the largest antibodies in humans and have more antigen binding sites than IgG. Therefore, they mount a strong initial defense and can provide laboratory evidence of a new infection.
However, they have some difficulties in a test tube. Some research shows that IgM can be less reliable than IgG due to increased cross-reactivity with non-target antigens. For example, researchers in one study found that 45% of samples tested positive for both Borrelia burgdorferi and Yersinia species on an IgM Western blot assay created for Yersinia specifically. Yersinia species include the pathogen that causes plague. Imagine being told that you had plague when you really had Lyme disease, yikes!
IgG can be a little more useful in the lab. They provide a secondary response that helps rid the body of the remaining infection. Generally, about 30 days after the initial infection, the concentration of IgM decreases drastically and IgG concentration increases.
IgG antibodies are typically more specific and provide a long-term defense, remaining in the bloodstream for weeks to months. Therefore, if the host is exposed to the same antigen in the future, the immune system can recognize and eliminate it quicker. Since IgG antibodies can remain in the body for so long, it is difficult to interpret the results of IgG tests without the context of patient medical history and current symptoms.
Molecular evidence of infectious pathogens (such as PCR testing to identify pathogen DNA) is often very difficult to detect, so many diagnostic methods rely on the antibodies created by the host’s immune system to rule out infections. A few common examples of these “immunoassays” are the ELISA, IFA, and Western blot.
The ELISA (Enzyme-Linked Immunosorbent Assay) and IFA (immunofluorescent assay) rely on chemical reactions that occur when antibodies present in a sample interact with antigens prepared by the lab. If there are antibodies present, a signal will be produced that can be seen by an automated device or by lab personnel. For example, in “reactive” IFA samples, a green fluorescence is measured in samples at different dilutions to determine the concentration of antibodies present. Likewise, Western blot (or sometimes referred to as immunoblots) look for the IgM and IgG themselves that are present after infection occurs. The serum sample is prepared and run through a gel matrix using an electrical current, transferred via a “blotting” technique, and then stained so “bands” become visible. This process separates proteins via size so that the person reading the blot can determine the presence of antibodies based on known markers. According to CDC criteria, a person is positive for Lyme disease on Western blot if there are 2 out 3 IgM or 5 out of 10 IgG diagnostic bands present.
Serology testing is a secondary method of testing for a pathogen. The body’s immune system response can amplify signals about the presence of pathogens that are easier to capture in a laboratory. However, those signals themselves can be difficult to interpret as they are not always the same and can indicate different things about when – and if – a pathogen has been encountered by the body’s immune system.
Maggi, R. G. et al. (2014). Comparison of serological and molecular panels for diagnosis of vector-borne diseases in dogs. Parasites & Vectors, 26(7), 127. doi:10.1186/1756-3305-7-127 https://www.ncbi.nlm.nih.gov/pubmed/24670154
Rawlins, M. L. et al. (2005). Evaluation of a Western blot method for the detection of Yersinia antibodies: Evidence of serological cross-reactivity between Yersinia outer membrane proteins and Borrelia burgdorferi. Clinical and Diagnostic Laboratory Immunology, 12(11), 1269-1674. doi:10.1128/CDLI.12.11.1269-1274.2005 https://www.ncbi.nlm.nih.gov/pubmed/16275939
About testing he states that the Western Blot appears to be the most positive finding in clinical LD, but…“setting arbitrary level of antibodies to diagnose a disease that has not been amenable to Koch’s postulates seems open to question. By the same token, ignoring antibody results unless they meet arbitrary levels seems suspect. The vast majority of patients in this series showed some WB antibody exposure, but many did not meet the arbitrary limits set….in our present state of knowledge, the diagnosis of chronic Lyme disease is a clinical one. Many of the patients in this series have suffered serious ‘hurts’ when they have been told that they could not have LD because their WB did not meet arbitrary limits.”- Dr. Waisbren
Five-year-old Chase Green is seen here at CHEO. (Supplied by Mandy Green)
The mother of a five-year-old boy from eastern Ontario now recovering from Lyme disease and meningitis says some doctors still aren’t recognizing the symptoms, and is calling for better education about them.
Mandy Green said that last week, an emergency room doctor and a family doctor mistook her son Chase’s condition for the flu or an allergy and sent him back to their home in Kemptville, south of Ottawa.
Days later, Chase ended up in a hospital bed at the area’s children’s hospital, hooked up to heart monitors and an IV to pump antibiotics through his system.
A spinal tap and blood tests at CHEO had revealed Chase was suffering from early disseminated Lyme disease with meningitis, an inflammation of the lining of the brain.
“It was a nightmare, it was awful,” said Green, “and it could have been prevented.”
Spot, circles
It began innocuously enough.
On July 20, Green noticed a small red spot on Chase’s face that got bigger and turned a brighter red by the evening. When her son woke up the next day, there was a perfect red circle on his shoulder.
“My first thought was it’s a bull’s-eye, it’s Lyme disease,” said Green, who had no recollection of her son being bitten by a tick. A bull’s-eye rash surrounding a tick bite is one of the early symptoms of Lyme disease.
The family drove to the emergency department at Kemptville District Hospital, where they waited for several hours as four more circles appeared on Chase’s wrist, stomach and back.
By then, Green assumed Chase was having an allergic reaction, because nothing she’d ever seen or read about Lyme disease said anything about multiple bull’s-eye rashes.
CBC News
‘It’s the saddest thing I’ve ever experienced’
Mandy Green’s five-year-old son was diagnosed with early disseminated Lyme disease and meningitis after doctors initially mistook his condition for the flu or an allergy. 0:51
Sent home with antihistamine prescription
The family grew tired of waiting and Chase was becoming impatient, so they decided to return home and administer allergy medication.
But by July 22, Chase was feverish, lethargic and complaining of headaches and a sore neck, so they headed back to the hospital.
After almost five hours they saw a doctor who Green said seemed stumped by the symptoms. The physician ordered blood tests and sent them home with a prescription for antihistamines.
Chase’s condition worsened that night, and a visit to the family doctor the morning of July 23 didn’t come up with any more answers. The doctor encouraged the parents to wait for the blood test results.
A map produced by Public Health Ontario shows various Lyme disease risk areas across the province. The Ottawa area is one of those areas estimated to be at risk. (Public Health Ontario)
By the afternoon of the 23rd, Green knew something was wrong when Chase screamed in pain and laid down on the couch.
“As soon as he laid on the couch and didn’t get up, I knew. This isn’t Chase. This is something wrong.”
The parents took Chase to CHEO, where he was quickly given the proper diagnosis.
“He was in so much pain and couldn’t stop crying. I curled up in his hospital bed with him,” Green said.
Chase received antibiotics intravenously and was sent home with a prescription for oral antibiotics.
But that wasn’t the end of it.
On Saturday, Chase appeared to relapse and was readmitted to CHEO, where he underwent surgery to have a catheter inserted into his chest so he could get more antibiotics intravenously at home, monitored by health-care workers.
Chase required surgery to enable him to continue getting antibiotics intravenously at home, and he’s starting to feel better. (Supplied by Mandy Green)
Dr. Jason Brophy, a pediatric infectious disease specialist at CHEO who did not treat Chase, said he’s seeing an increase in cases of Lyme disease among children in the Ottawa area.
“In the past five years Ottawa has become an endemic area, meaning the ticks in our region carry Lyme disease over 20 per cent of the time,” he said.
A lot of people who contract Lyme can get over it without treatment, but for others it can lead to complications if there’s no medical intervention.
The form of meningitis associated with Lyme disease may occur several weeks after a tick bite, Brophy added.
Full recovery expected
As for Chase, a full recovery is expected.
His mother said she doesn’t blame the medical system for what happened to her son, but she’s calling for better information about the symptoms of Lyme disease to be distributed to health facilities.
She’s also warning parents to keep an eye out for ticks on their children, so they can avoid her son’s painful experience.
On a widely distributed Facebook post about the ordeal, she wrote: “Check your kids for ticks, check yourself. We never found the tick that caused this, so listen to your gut, get second opinions, advocate for yourself and your children.”